Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial
about
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillationRUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndromeXimelagatran: direct thrombin inhibitorAnticoagulation for non-valvular atrial aibrillation - towards a new beginning with ximelagatranAnticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decadeRivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practiceComparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber modelEvidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in manClinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEMDirect thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillationWill oral antithrombin agents replace warfarin?Novel therapies for the prevention of strokeDual pathway therapy in acute coronary syndrome.Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.Ximelagatran: a new type of oral anticoagulant.Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial.New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis.Antithrombotic therapy for long-term secondary prevention of acute coronary syndrome in high-risk patients.Management of acute coronary syndromes: an updatePharmacological basis and clinical evidence of dabigatran therapy.Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.Novel uses for current and future direct thrombin inhibitors: focus on ximelagatran and bivalirudin.Ximelagatran: light at the end of the tunnel or the next tunnel?Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management.Ximelagatran: a new antithrombotic option in atrial fibrillation.Ximelagatran: an oral direct thrombin inhibitor.Ximelagatran: pharmacology, pharmacokinetics, and pharmacodynamics.Management of thrombosis in cancer: primary prevention and secondary prophylaxis.New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarinXimelagatran for stroke prevention in atrial fibrillation.A preliminary assessment of the critical differences between novel oral anticoagulants currently in development.Cautionary tales in the clinical interpretation of therapeutic trial reports.Role of clotting factors and fibrin structure in predisposition to atherothrombotic disease.Management of patients with type 2 diabetes after acute coronary syndromes.Potential role of rivaroxaban in patients with acute coronary syndromeThe status of new anticoagulants.Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review.Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease.The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile.New oral anticoagulant agents after ACS.
P2860
Q24197843-95F552CC-BC77-430F-AB88-C22B8E1FB53EQ24623137-D977B6EC-7FFE-4CC9-895B-1A2C8AA562FAQ24681333-49DC95EB-F744-4CE6-AD90-212DFED58CC1Q24807132-AD05C06F-3821-42F0-B790-32BC7F93C447Q26824864-823366EB-E00B-40F0-BAD3-1ECD90D9FE46Q26825230-B6454667-A8C3-4606-90FC-6AC221CDFBD5Q27330363-83BC2E26-0392-4EDB-B47F-CA95F79632CFQ28069617-18A7B723-7CA8-4E11-90AE-4B98D44128DDQ28166022-D7F54C61-FEB1-4106-8376-03CB2518489AQ28176666-22ED1C82-C971-4F52-B125-8E5B3FDE4164Q28208671-764E28A4-2D42-4ABB-B113-B34DCB871C36Q28210724-630B58B2-042E-44BC-B87C-CBF8C434184DQ30252011-31895D6C-E375-4C04-BDEF-678C47382CE2Q30680968-F2E9AFDA-4401-4F63-B8AB-149F93A5DFBCQ33226419-567734C8-47F3-4A35-BB14-E49826DF970EQ34262668-6061A0EF-D6AC-4747-A6D8-329DA56A7C60Q34331671-F9E8D013-2795-4FE5-AF16-1FD51DF4742EQ35111496-85F58037-44FF-423D-9247-FF5013A00B2DQ35582484-FC79D00B-77EA-453C-8A96-D26A6A4B940EQ35685099-D41FF144-4F93-4CAB-AD86-5F5337E8A1BFQ35777336-C17FDD33-450E-4085-9E3D-5A9561FEF2A5Q35779232-7976A3CE-56ED-47AE-983D-625F5F13A9BFQ35843153-5B26A3E5-413B-45DD-9AF2-83FA1D51BF77Q35878355-1E0A8BF9-B08B-4035-BC45-050049D7A9F1Q35892171-D7FC3F70-37C0-421E-A480-768D65DA19CAQ35895188-D76C8E14-3A00-4FA2-A634-1299F5D17F36Q35996015-F5FA3360-7F13-438F-A3E8-14143AFBDCD8Q36018537-DA78BCB8-0E16-45E4-8EED-3013720D5EA3Q36042279-63A866AE-610A-4A8C-9B09-5CBEE4A52A41Q36216784-8ADC4E3F-82E8-41AB-987C-DE1CE4B62203Q36229356-BB714330-458D-4D7E-9D60-1CE0671149F8Q36278143-0BEDA7C7-E56A-4553-B6BB-C7ADEA3F1CDFQ36314852-9DFD077D-C36B-477E-8B94-98022F11D2AFQ36333931-D8045945-C632-4ECB-B598-3BCAF0F135D5Q36433688-FC97554E-3AD7-4685-B484-6579578E9D73Q36520745-CC3934AA-2457-4FA0-8937-DB3C18990E2FQ36705836-6598C8CA-C3A1-48B7-B379-335FBC2FA9C5Q36802592-30109AC7-1F92-40EC-BAE6-8F1F58382DC6Q36905848-4D07A9D8-1733-4612-9CD0-DAEEB89AA1BAQ37140964-23EDBFD3-C934-4EAA-B311-DC8B9CC29732
P2860
Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Oral ximelagatran for secondar ...... EM randomised controlled trial
@ast
Oral ximelagatran for secondar ...... EM randomised controlled trial
@en
Oral ximelagatran for secondar ...... EM randomised controlled trial
@nl
type
label
Oral ximelagatran for secondar ...... EM randomised controlled trial
@ast
Oral ximelagatran for secondar ...... EM randomised controlled trial
@en
Oral ximelagatran for secondar ...... EM randomised controlled trial
@nl
prefLabel
Oral ximelagatran for secondar ...... EM randomised controlled trial
@ast
Oral ximelagatran for secondar ...... EM randomised controlled trial
@en
Oral ximelagatran for secondar ...... EM randomised controlled trial
@nl
P2093
P3181
P1433
P1476
Oral ximelagatran for secondar ...... EM randomised controlled trial
@en
P2093
Anders Bylock
Andrew Goodvin
Per Nyström
Robert G Wilcox
W Douglas Weaver
P304
P3181
P356
10.1016/S0140-6736(03)14287-0
P407
P577
2003-09-06T00:00:00Z